Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer

There are a wide range of therapies for metastatic colorectal cancer (CRC) available, but outcomes remain suboptimal. Learning the role of the immune system in cancer development and progression led to advances in the treatment over the last decade. While the field is rapidly evolving, PD-1, and PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, André F., Bretes, Luís, Furtado, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527887/
https://www.ncbi.nlm.nih.gov/pubmed/31139574
http://dx.doi.org/10.3389/fonc.2019.00396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527887/
https://www.ncbi.nlm.nih.gov/pubmed/31139574
http://dx.doi.org/10.3389/fonc.2019.00396

Ejemplares similares